Paul Coppo

List of Publications by Year
in descending order

182 papers	8,878 citations	53794 45 h-index	45317 90 g-index
199 all docs	199 docs citations	199 times ranked	6902 citing authors

#	Article	IF	Citations
1	Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome. Arthritis and Rheumatology, 2014, 66, 2613-2620.	5.6	875
2	Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2019, 380, 335-346.	27.0	625
3	Thrombotic thrombocytopenic purpura. Blood, 2017, 129, 2836-2846.	1.4	457
4	Heterozygous and Homozygous Factor H Deficiencies Associated with Hemolytic Uremic Syndrome or Membranoproliferative Glomerulonephritis: Report and Genetic Analysis of 16 Cases. Journal of the American Society of Nephrology: JASN, 2004, 15, 787-795.	6.1	351
5	Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience. PLoS ONE, 2010, 5, e10208.	2.5	286
6	Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. Blood, 2010, 115, 1226-1237.	1.4	285
7	Reactive Hemophagocytic Syndrome in Adults: A Retrospective Analysis of 162 Patients. American Journal of Medicine, 2014, 127, 1118-1125.	1.5	261
8	Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Critical Care Medicine, 2012, 40, 104-111.	0.9	260
9	Prognostic value of anti-ADAMTS13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS13 activity. Blood, 2007, 109, 2815-2822.	1.4	248
10	Thrombotic thrombocytopenic purpura. Nature Reviews Disease Primers, 2017, 3, 17020.	30.5	242
11	Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematology,the, 2016, 3, e237-e245.	4.6	218
12	Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood, 2012, 119, 5888-5897.	1.4	206
13	ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2496-2502.	3.8	188
14	Severe ADAMTS13 Deficiency in Adult Idiopathic Thrombotic Microangiopathies Defines a Subset of Patients Characterized by Various Autoimmune Manifestations, Lower Platelet Count, and Mild Renal Involvement. Medicine (United States), 2004, 83, 233-244.	1.0	165
15	Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. British Journal of Haematology, 2015, 168, 63-68.	2.5	161
16	Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood, 2014, 124, 204-210.	1.4	154
17	ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2486-2495.	3.8	142
18	Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica, 2012, 97, 1181-1186.	3.5	118

#	Article	IF	Citations
19	Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy. Transplantation, 2015, 99, 1953-1959.	1.0	110
20	High-Dose Plasma Infusion versus Plasma Exchange as Early Treatment of Thrombotic Thrombocytopenic Purpura/Hemolytic-Uremic Syndrome. Medicine (United States), 2003, 82, 27-38.	1.0	103
21	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	1.4	103
22	Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood, 2018, 132, 2143-2153.	1.4	102
23	A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood, 2021, 137, 733-742.	1.4	95
24	Reactive haemophagocytic syndrome in 58 HIV-1-infected patients: clinical features, underlying diseases and prognosis. Aids, 2010, 24, 1299-1306.	2.2	92
25	Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome. Arthritis and Rheumatism, 2008, 58, 1521-1527.	6.7	90
26	BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. British Journal of Haematology, 2006, 134, 171-179.	2.5	88
27	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	1.4	82
28	Cancer Awareness in Atypical Thrombotic Microangiopathies. Oncologist, 2009, 14, 769-779.	3.7	78
29	Successful use of eculizumab in a patient with postâ€transplant thrombotic microangiopathy. British Journal of Haematology, 2013, 161, 279-280.	2.5	76
30	Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 26-37.	2.3	74
31	Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion, 2012, 52, 2436-2444.	1.6	73
32	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica, 2016, 101, 976-984.	3.5	70
33	Partial Fanconi Syndrome Induced by Imatinib Therapy: A Novel Cause of Urinary Phosphate Loss. American Journal of Kidney Diseases, 2008, 51, 298-301.	1.9	67
34	A Web-Based Delphi Study for Eliciting Helpful Criteria in the Positive Diagnosis of Hemophagocytic Syndrome in Adult Patients. PLoS ONE, 2014, 9, e94024.	2.5	65
35	Thrombotic Microangiopathies: Towards a Pathophysiology-Based Classification. Cardiovascular & Hematological Disorders Drug Targets, 2009, 9, 36-50.	0.7	64
36	An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura. Expert Review of Hematology, 2019, 12, 383-395.	2.2	64

#	Article	IF	Citations
37	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. Haematologica, 2018, 103, 212-220.	3.5	62
38	Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura. Medicine (United States), 2015, 94, e1598.	1.0	58
39	Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Medicale, 2012, 41, e163-e176.	1.9	57
40	Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatric Nephrology, 2009, 24, 19-29.	1.7	56
41	Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells. Oncogene, 2003, 22, 4102-4110.	5.9	54
42	Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematology,the, 2016, 3, e537-e546.	4.6	53
43	Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era. Aids, 2017, 31, 2493-2501.	2.2	51
44	Infectious diseases as a trigger in thrombotic microangiopathies in intensive care unit (ICU) patients?. Intensive Care Medicine, 2003, 29, 564-569.	8.2	50
45	The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. Journal of Autoimmunity, 2015, 59, 19-25.	6.5	50
46	Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Hematology American Society of Hematology Education Program, 2015, 2015, 637-643.	2.5	48
47	Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Medicine, 2019, 45, 1518-1539.	8.2	47
48	Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. American Journal of Hematology, 2016, 91, 1246-1251.	4.1	46
49	Pediatric thrombotic thrombocytopenic purpura. European Journal of Haematology, 2018, 101, 425-434.	2.2	45
50	Efficacy and safety of openâ€label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. Journal of Thrombosis and Haemostasis, 2020, 18, 479-484.	3.8	45
51	Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. European Journal of Internal Medicine, 2015, 26, 659-665.	2.2	42
52	ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshawâ€“Schulman Syndrome. Thrombosis and Haemostasis, 2018, 118, 1902-1917.	3.4	40
53	Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort. British Journal of Clinical Pharmacology, 2019, 85, 403-412.	2.4	39
54	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	5.2	39

#	Article	IF	Citations
55	Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival. Blood, 2019, 134, 2209-2217.	1.4	38
56	Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors. PLoS ONE, 2016, 11, e0156679.	2.5	38
57	Are platelet transfusions harmful in acquired thrombotic thrombocytopenic purpura at the acute phase? experience of the <scp>F</scp>rench thrombotic microangiopathies reference center. American Journal of Hematology, 2015, 90, E127-9.	4.1	37
58	Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura. Blood, 2020, 136, 353-361.	1.4	35
59	Firstâ€line treatment of doubleâ€hit and tripleâ€hit lymphomas: Survival and tolerance data from a retrospective multicenter French study. American Journal of Hematology, 2021, 96, 302-311.	4.1	32
60	Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. Transfusion, 2015, 55, 2445-2451.	1.6	31
61	Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French thrombotic microangiopathies reference centre. American Journal of Hematology, 2017, 92, 381-387.	4.1	31
62	Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers. Haematologica, 2018, 103, 1099-1109.	3.5	31
63	Thrombotic thrombocytopenic purpura in children. Current Opinion in Pediatrics, 2013, 25, 216-224.	2.0	30
64	Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis. International Urology and Nephrology, 2014, 46, 239-242.	1.4	28
65	Evaluation of a chromogenic commercial assay using VWF-73 peptide for ADAMTS13 activity measurement. Thrombosis Research, 2014, 134, 1074-1080.	1.7	28
66	High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center. Transfusion, 2013, 54, n/a-n/a.	1.6	25
67	Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2020, 18, 2503-2512.	3.8	25
68	Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic Tâ€cell lymphoma. European Journal of Haematology, 2019, 103, 35-42.	2.2	24
69	Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrology, 2021, 22, 267.	1.8	24
70	Twiceâ€daily therapeutical plasma exchangeâ€based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French <scp>TMA</scp> Reference Center experience. European Journal of Haematology, 2016, 97, 183-191.	2.2	23
71	A comprehensive analysis of Lymphomaâ€associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis. British Journal of Haematology, 2018, 183, 68-75.	2.5	23
72	Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study. Leukemia and Lymphoma, 2018, 59, 1399-1405.	1.3	21

#	Article	IF	Citations
73	Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count. Transfusion, 2015, 55, 1798-1802.	1.6	20
74	Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Transfusion and Apheresis Science, 2017, 56, 52-56.	1.0	20
75	Causes and risk factors of death in patients with thrombotic microangiopathies. Intensive Care Medicine, 2012, 38, 1810-1817.	8.2	19
76	EBV infection determines the immune hallmarks of plasmablastic lymphoma. OncoImmunology, 2018, 7, e1486950.	4.6	19
77	Should all patients with immuneâ€mediated thrombotic thrombocytopenic purpura receive caplacizumab?. Journal of Thrombosis and Haemostasis, 2021, 19, 58-67.	3.8	19
78	Shiga Toxin-Associated Hemolytic Uremic Syndrome: Specificities of Adult Patients and Implications for Critical Care Management. Toxins, 2021, 13, 306.	3.4	19
79	LETTERS TO THE EDITOR: Successful longâ€term rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura. Transfusion, 2010, 50, 733-735.	1.6	18
80	Evaluation of a commercial assay for ADAMTS13 activity measurement. Thrombosis and Haemostasis, 2013, 110, 852-853.	3.4	18
81	Management of thrombotic thrombocytopenic purpura. Transfusion Clinique Et Biologique, 2017, 24, 148-153.	0.4	18
82	Thrombotic microangiopathies and antineoplastic agents. Nephrologie Et Therapeutique, 2017, 13, S109-S113.	0.5	18
83	Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkers. Nephrology Dialysis Transplantation, 2020, 35, 1538-1546.	0.7	16
84	Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura. Haematologica, 2020, 105, 2619-2630.	3.5	16
85	Immunogenic hotspots in the spacer domain of ADAMTS13 in immuneâ€mediated thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 2021, 19, 478-488.	3.8	16
86	Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura. Blood Advances, 2021, 5, 3427-3435.	5.2	16
87	Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS ONE, 2017, 12, e0177894.	2.5	16
88	Acute renal failure with lambda light chain-derived crystals in a patient with IgD myeloma. Nephrology Dialysis Transplantation, 2011, 26, 3057-3059.	0.7	14
89	The ADAMTS13 ^{1239â€“1253} peptide is a dominant HLA-DR1-restricted CD4 ⁺ T-cell epitope. Haematologica, 2017, 102, 1833-1841.	3.5	14
90	Antineutrophil cytoplasmic antibody-associated neutropenia. European Journal of Internal Medicine, 2004, 15, 451-459.	2.2	13

#	Article	IF	Citations
91	Proteinuria Increases the PLASMIC and French Scores Performance to Predict Thrombotic Thrombocytopenic Purpura in Patients With Thrombotic Microangiopathy Syndrome. Kidney International Reports, 2022, 7, 221-231.	0.8	13
92	Autoimmune cytopenias associated with autoantibodies to nuclear envelope polypeptides. American Journal of Hematology, 2004, 77, 241-249.	4.1	12
93	Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment. Expert Opinion on Biological Therapy, 2019, 19, 1127-1134.	3.1	12
94	Antiâ€ADAMTS13 autoantibodies in immuneâ€mediated thrombotic thrombocytopenic purpura do not hamper ELISAâ€based quantification of ADAMTS13 antigen. Journal of Thrombosis and Haemostasis, 2020, 18, 985-990.	3.8	12
95	Diagnosis and followâ€up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 81-93.	2.3	12
96	<scp>TTP</scp>: From empiricism for an enigmatic disease to targeted molecular therapies. British Journal of Haematology, 2022, 197, 156-170.	2.5	12
97	BCR-ABL induces opposite phenotypes in murine ES cells according to STAT3 activation levels. Cellular Signalling, 2009, 21, 52-60.	3.6	11
98	Splenic sarcoidosis: An unusual aetiology of agranulocytosis. American Journal of Hematology, 2010, 85, 891-891.	4.1	11
99	N-glycanâ€“mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTP. Blood, 2021, 137, 2694-2698.	1.4	11
100	Therapeutic plasma exchange in thrombotic thrombocytopenic purpura. Presse Medicale, 2019, 48, 319-327.	1.9	10
101	TTP in the setting of pregnancy: The story still has to be written. Journal of Thrombosis and Haemostasis, 2020, 18, 2775-2777.	3.8	10
102	Dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide (DPACE) is an effective salvage regimen for multiple myeloma refractory to novel agents. Leukemia and Lymphoma, 2013, 54, 1117-1119.	1.3	9
103	Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMA. European Journal of Internal Medicine, 2021, 93, 78-86.	2.2	9
104	A Prospective Phase II Trial of An L-Asparaginase Containing Regimen in Patients with Refractory or Relapsing Extra Nodal NK/T-Cell Lymphoma. Blood, 2008, 112, 579-579.	1.4	9
105	Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura. Expert Review of Hematology, 2019, 12, 461-471.	2.2	8
106	Combination of brentuximabâ€vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral Tâ€cell lymphoma. European Journal of Haematology, 2021, 106, 467-472.	2.2	8
107	Shiga Toxinâ€“Associated Hemolytic Uremic Syndrome in Adults, France, 2009â€“2017. Emerging Infectious Diseases, 2021, 27, 1876-1885.	4.3	8
108	Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases. Journal of Nephrology, 2022, 35, 653-656.	2.0	8

#	Article	IF	Citations
109	Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura. Thrombosis Research, 2019, 181, 29-35.	1.7	7
110	Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature. British Journal of Haematology, 2020, 188, 338-340.	2.5	7
111	Hepatitis C virus or hepatitis B virus coinfection and lymphoma risk in people living with HIV. Aids, 2020, 34, 599-608.	2.2	7
112	Intensive rituximab regimen in immuneâ€mediated thrombotic thrombocytopenic purpura can circumvent unresponsiveness to standard rituximab treatment. British Journal of Haematology, 2021, 192, e21-e25.	2.5	7
113	Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre. Blood, 2016, 128, 136-136.	1.4	7
114	ADAMTS13 and von Willebrand factor assessment in steady state and acute vasoâ€occlusive crisis of sickle cell disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 197-203.	2.3	7
115	Thrombotic microangiopathy associated with anti-neutrophil cytoplasmic antibody-associated vasculitis: a French nationwide retrospective caseâ€“control study and literature review. Rheumatology, 2019, 58, 1873-1875.	1.9	6
116	Anti-cysteine/spacer antibodies that open ADAMTS13 are a common feature in iTTP. Blood Advances, 2021, 5, 4480-4484.	5.2	6
117	Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial. Blood, 2010, 116, 1344-1344.	1.4	6
118	Allogenic bone marrow transplantation with a donor presenting with an acute hepatitis A. Journal of Hepatology, 2001, 34, 625-630.	3.7	5
119	Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome. Medicine (United States), 2016, 95, e5007.	1.0	5
120	Acute pancreatitis in immunocompromised patients: beware of varicella zoster virus primoâ€infection. Clinical Case Reports (discontinued), 2017, 5, 1261-1263.	0.5	5
121	Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 1537-1539.	1.6	5
122	Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients. Haematologica, 2019, 104, 1268-1276.	3.5	5
123	HLA-DRB1*11 is a strong risk factor for acquired thrombotic thrombocytopenic purpura in children. Haematologica, 2020, 105, e531.	3.5	5
124	Animal models of thrombotic thrombocytopenic purpura: the tales from zebrafish. Haematologica, 2020, 105, 861-863.	3.5	5
125	Efficacy of subcutaneous preemptive rituximab in immuneâ€mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases. American Journal of Hematology, 2021, 96, E26-E29.	4.1	5
126	Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085. Blood, 2019, 134, 130-130.	1.4	5

#	Article	IF	Citations
127	European Renal Best Practice endorsement of guidelines for diagnosis and therapy of thrombotic thrombocytopaenic purpura published by the International Society on Thrombosis and Haemostasis. Nephrology Dialysis Transplantation, 2022, 37, 1229-1234.	0.7	5
128	Primary Gastrointestinal Follicular Lymphomas: A Prospective Study of 31 Patients with Long-term Follow-up Registered in the French Gastrointestinal Lymphoma Study Group (GELD) of the French Federation of Digestive Oncology (FFCD). Gut and Liver, 2022, 16, 207-215.	2.9	5
129	Clinical significance of autoantibodies to the pericentromeric heterochromatin protein 1a protein. European Journal of Internal Medicine, 2013, 24, 868-871.	2.2	4
130	The Spectrum of Chronic CD8+ T-Cell Expansions: Clinical Features in 14 Patients. PLoS ONE, 2014, 9, e91505.	2.5	4
131	Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab. Frontiers in Medicine, 2020, 7, 549931.	2.6	4
132	Understanding the Health Literacy in Patients With Thrombotic Thrombocytopenic Purpura. HemaSphere, 2020, 4, e462.	2.7	4
133	Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease. Leukemia and Lymphoma, 2021, 62, 2235-2241.	1.3	4
134	Pattern of Brain Injury in Patients With Thrombotic Thrombocytopenic Purpura in the Precaplacizumab Era. Critical Care Medicine, 2021, 49, e931-e940.	0.9	4
135	Immuneâ€mediated thrombotic thrombocytopenic purpura prognosis is affected by blood pressure. Research and Practice in Thrombosis and Haemostasis, 2022, 6, .	2.3	4
136	Bilateral serous detachment of retina: an unusual mode of revelation of thrombotic thrombocytopenic purpura of favorable outcome with plasma exchange. Graefe's Archive for Clinical and Experimental Ophthalmology, 2014, 252, 181-183.	1.9	3
137	When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP. Transfusion and Apheresis Science, 2019, 58, 273-277.	1.0	3
138	Types of fresh plasma with focus on therapeutic plasma exchange. Transfusion and Apheresis Science, 2019, 58, 258-261.	1.0	3
139	The EHA Research Roadmap: Platelet Disorders. HemaSphere, 2021, 5, e601.	2.7	3
140	Integrated Safety Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3739-3739.	1.4	3
141	Safety of Caplacizumab for the Treatment of Patients with Acquired Thrombotic Thrombocytopenic Purpura - Results Normalized to Time of Exposure in a Double-Blind, Placebo-Controlled, Phase 3 Hercules Study. Blood, 2018, 132, 3744-3744.	1.4	3
142	Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study. Blood, 2018, 132, 1142-1142.	1.4	3
143	First-Line Rituximab Efficacy and Safety in Patients with Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Experiencing a Non Optimal Response to Therapeutical Plasma Exchange: Results of a Prospective Multicenter Phase 2 Study From the French Reference Center for the Management of Thrombotic Microangiopathies.. Blood, 2009, 114, 890-890.	1.4	3
144	Preemptive Rituximab Infusions Efficiently Prevent Relapses In Acquired Thrombotic Thrombocytopenic Purpura. Experience Of The French Thrombotic Microangiopathies Reference Center. Blood, 2013, 122, 448-448.	1.4	3

#	Article	IF	Citations
145	Urine Protein/Creatinine Ratio in Thrombotic Microangiopathies: A Simple Test to Facilitate Thrombotic Thrombocytopenic Purpura and Hemolytic and Uremic Syndrome Diagnosis. Journal of Clinical Medicine, 2022, 11, 648.	2.4	3
146	Tâ€cell prolymphocytic leukemia and tuberculosis: a puzzling association. Clinical Case Reports (discontinued), 2017, 5, 1536-1541.	0.5	2
147	Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura. Transfusion and Apheresis Science, 2019, 58, 102665.	1.0	2
148	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 373-373.	1.4	2
149	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen. Blood, 2019, 134, 2365-2365.	1.4	2
150	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. Blood, 2019, 134, 2366-2366.	1.4	2
151	Mature CD8 + Tâ€cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. Clinical Case Reports (discontinued), 2016, 4, 1088-1090.	0.5	1
152	FP268POST PARTUM ACUTE KIDNEY INJURY: SORTING PLACENTAL AND NON-PLACENTAL THROMBOTIC MICROANGIOPATHIES USING THE TRAJECTORY OF BIOMARKERS.. Nephrology Dialysis Transplantation, 2018, 33, i120-i121.	0.7	1
153	Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura. TH Open, 2018, 02, e407-e410.	1.4	1
154	Risk factors associated with the human leucocyte antigen system in Lebanese patients with immune-mediated thrombotic thrombocytopenic purpura. Presse Medicale, 2019, 48, 1182-1184.	1.9	1
155	Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation. Haematologica, 2019, 104, e277-e280.	3.5	1
156	Thrombotic Thrombocytopenic Purpura: When Basic Science Meets Clinical Research. Hamostaseologie, 2021, 41, 283-293.	1.9	1
157	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies. Blood, 2019, 134, 4908-4908.	1.4	1
158	Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients. Blood, 2015, 126, 106-106.	1.4	1
159	Reactive Hemophagocytic Syndrome after Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study on Behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC). Blood, 2016, 128, 4617-4617.	1.4	1
160	Development and Validation of a Predictive Model for Death in Acquired Severe ADAMTS13 Deficiency-Associated Idiopathic Thrombotic Thrombocytopenic Purpura: The French TMA Reference Center Experience. Blood, 2011, 118, 2229-2229.	1.4	1
161	Thrombotic Thrombocytopenic Purpura Misdiagnosed As Autoimmune Cytopenia: Causes of Diagnostic Errors and Consequence on Outcome. Experience of the French Thrombotic Microangiopathies Reference Centre. Blood, 2016, 128, 3730-3730.	1.4	1
162	Deregulated JAK3 mediates growth advantage and hemophagocytosis in extranodal nasal-type natural killer/T cell lymphoma. Haematologica, 2022, , .	3.5	1

#	Article	IF	Citations
163	Response to "Predictors of survival in thrombotic thrombocytopenic purpura" Haematologica 2013;98(5):e58. Haematologica, 2013, 98, e80-e80.	3.5	0
164	Reply. Arthritis and Rheumatology, 2015, 67, 588-588.	5.6	0
165	How do I treat an hemophagocytic syndrome. Hematologie, 2016, 22, 218-233.	0.0	0
166	Plasma Exchanges for Refractory Evans Syndrome. Therapeutic Apheresis and Dialysis, 2018, 22, 560-562.	0.9	0
167	Immune TTP pathogenesis: the rising sun on HLA. Blood, 2020, 135, 2335-2336.	1.4	0
168	News in thrombotic thrombocytopenic purpura and ADAMTS13. Hematologie, 2021, 27, 188-199.	0.0	0
169	Involvement of STAT3 Transcription Factor in Disseminated Nasal-Type Natural Killer Cell Lymphomas.. Blood, 2007, 110, 4167-4167.	1.4	0
170	Idiopathic Thrombotic Microangiopathies: Antinuclear Antibodies, Platelet Count and Creatinin Level Can Predict a Severe ADAMTS13 Deficiency.. Blood, 2007, 110, 3923-3923.	1.4	0
171	CXCR4 Blockade as a New Targeted Therapy for Acute Myeloide Leukemia Characterised by High Cell Surface Density of CXCR4.. Blood, 2009, 114, 4570-4570.	1.4	0
172	HLA-DRB1*11: a Strong Risk Factor for Acquired Severe ADAMTS13 Deficiency-Related Idiopathic Thrombotic Thrombocytopenic Purpura in Caucasians.. Blood, 2009, 114, 2412-2412.	1.4	0
173	Residual Plasmatic Activity of ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura Correlates with Disease Phenotype. Blood, 2011, 118, 2219-2219.	1.4	0
174	Assessment Of Endothelial Damage and Cardiac Injury In a Mouse Model Mimicking Thrombotic Thrombocytopenic Purpura. Blood, 2013, 122, 447-447.	1.4	0
175	Pretransplantation Positron Emission Tomography Predicts Outcome Following Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma. Blood, 2015, 126, 5506-5506.	1.4	0
176	French Observatory of Adult' Chronic Immune Thrombocytopenia (ITP) Treated By Thrombopoietin Receptor Agonists (TPO-RAs). Blood, 2015, 126, 2250-2250.	1.4	0
177	Inflammatory and Autoimmune Manifestations Associated with Lymphoid Neoplasms: A French Multicenter Retrospective Study. Blood, 2016, 128, 5335-5335.	1.4	0
178	Texture Analysis on Computed Tomography Predicts the Outcome of Patients with Hodgkin Lymphoma. Blood, 2016, 128, 1832-1832.	1.4	0
179	Clinical Spectrum, Evolution and Management of Autoimmune Cytopenia Associated with Angioimmunoblastic T-Cell Lymphoma: A Retrospective, Multicenter Study. Blood, 2016, 128, 1816-1816.	1.4	0
180	Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study. Blood, 2019, 134, 1093-1093.	1.4	0

#	Article	IF	Citations
181	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. Blood, 2021, 138, 2080-2080.	1.4	0
182	Overexpression of IgG2 in patients resembling IgG4â€related disease with normal IgG4. Scandinavian Journal of Immunology, 2022, 95, e13126.	2.7	0